Compare Nuwellis Inc (NUWE) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Starbucks Corp — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Starbucks Corp trades at $90.87 (market cap $106.26B). The key difference: Starbucks Corp is far larger — about 48300× Nuwellis Inc's market cap, and Starbucks Corp pays a 2.7% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Starbucks Corp for 190 Days on average.
| NUWE | SBUX | |
|---|---|---|
Market Cap | $2.20M | $106.26B |
Volume | 121,544 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $146.65 | $108.55 |
52-Week Low | $0.68 | $78.46 |
Typical Hold Time | 26 Days | 190 Days |
Enterprise Value | -$1.52M | $125.08B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Starbucks (SBUX) trades at $90.75, down 3.02% today, amid a bearish technical outlook and mixed fundamental performance. The company reported Q2 2026 EPS beat ($0.85 vs. $0.66 expected) but missed in Q4 2025, with revenue growth slowing to 2.8% year-over-year in 2025. Recent news highlights store closures (250 locations) and strategic portfolio reset, while analyst consensus remains positive with a $115.50 price target. Negative shareholder equity and elevated debt levels present financial concerns.
Outlook: Near-term pressure from restructuring and geopolitical risks, but long-term growth potential in high-performing locations and international markets. Risks include execution on store strategy, labor relations, and China exposure. Investment case hinges on successful turnaround and margin recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
